Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis

NCT06543550 · ctgov recruiting phase phase-4
Enrollment
70
Start
2024-07-30
Completion
2028-03-01
Last updated
2026-10-20
Has results
False
Countries
Brazil

Conditions

Endometriosis

Tagged with

endometriosis

Interventions

Eligibility criteria
Inclusion Criteria: * Adult female patients of menstrual age, pre-menopause (18 to 45 years old), who seek medical treatment to alleviate complaints related to endometriosis, who are not undergoing other therapies to treat them. * Patients must have a diagnosis of Grade 1 or 2 endometriosis assessed by imaging tests (ultrasound with bowel preparation and/or MRI of the pelvis with bowel preparation)14, have a BMI of up to 25kg/m2, and weigh between 50 and 70kg. Exclusion Criteria: * Pregnant patients (supporting test must be presented) * Breastfeeding women, using other hormonal contraceptive methods or copper or silver IUDs, who have polycystic ovaries, and/or hyperandrogenism. * Patients using medications that may interfere with androgen metabolism within 4 weeks of screening or during the study. * Patients with a history of liver disease, cardiovascular disease (myocardial infarction, unstable angina or heart failure), active hepatitis, liver neoplasia or renal failure * Patient who are scheduled for surgical treatment during the study period.
License: public-domain-us · commercial use OK · attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine

No linked papers in the corpus yet.